IL2 and metastatic neoplasm: Earlier treatment for patients with metastatic disease [including the initially diagnosed metastatic RCC (mRCC) patients] relied on several cytokines, such as interferon alfa (IFN-α) and interleukin-2 (IL-2), which aimed to activate the antitumor immune system [9].